Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Mar 20, 2025
Positive Results with Zervimesine (CT1812) in Phase 2 SHIMMER Dementia with Lewy Bodies (DLB)
Phase 2 SHINE Data Show Dramatic Slowing of Cognitive Decline with Zervimesine in a Key Pre-specified Alzheimer’s Disease Subgroup
Read more at globenewswire.comNASDAQ:CGTX (6/2/2025, 11:44:44 AM)
0.26
+0.02 (+8.33%)
Find more stocks in the Stock Screener
